ORCHPHARMA Stock Overview
A pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ORCHPHARMA from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Orchid Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,790.65 |
| 52 Week High | ₹1,841.10 |
| 52 Week Low | ₹692.20 |
| Beta | 2.06 |
| 1 Month Change | 22.79% |
| 3 Month Change | 27.96% |
| 1 Year Change | 157.68% |
| 3 Year Change | 354.94% |
| 5 Year Change | n/a |
| Change since IPO | 9,848.06% |
Recent News & Updates
Orchid Pharma Limited's (NSE:ORCHPHARMA) P/E Is Still On The Mark Following 25% Share Price Bounce
Nov 27
Earnings Tell The Story For Orchid Pharma Limited (NSE:ORCHPHARMA) As Its Stock Soars 26%
Jul 29Recent updates
Orchid Pharma Limited's (NSE:ORCHPHARMA) P/E Is Still On The Mark Following 25% Share Price Bounce
Nov 27Earnings Tell The Story For Orchid Pharma Limited (NSE:ORCHPHARMA) As Its Stock Soars 26%
Jul 29We Ran A Stock Scan For Earnings Growth And Orchid Pharma (NSE:ORCHPHARMA) Passed With Ease
Jun 12Orchid Pharma Limited's (NSE:ORCHPHARMA) Intrinsic Value Is Potentially 17% Below Its Share Price
May 08Orchid Pharma Limited's (NSE:ORCHPHARMA) P/S Is Still On The Mark Following 72% Share Price Bounce
Feb 28Does Orchid Pharma (NSE:ORCHPHARMA) Have A Healthy Balance Sheet?
Feb 06Orchid Pharma Limited (NSE:ORCHPHARMA) Looks Just Right With A 33% Price Jump
Dec 18Shareholder Returns
| ORCHPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 4.2% | 0.8% | -4.2% |
| 1Y | 157.7% | 39.7% | 19.1% |
Return vs Industry: ORCHPHARMA exceeded the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: ORCHPHARMA exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| ORCHPHARMA volatility | |
|---|---|
| ORCHPHARMA Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: ORCHPHARMA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: ORCHPHARMA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 871 | Manish Dhanuka | www.orchidpharma.com |
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins, veterinary products, and non-antibiotics. The company has multi-therapeutic presence in anti-infectives, anti-inflammatory, central nervous system, cardiovascular segment, nutraceuticals, and other oral and sterile products, as well as offers new drug discovery systems and pharmaceutical research and development services.
Orchid Pharma Limited Fundamentals Summary
| ORCHPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹90.82b |
| Earnings (TTM) | ₹1.20b |
| Revenue (TTM) | ₹9.05b |
76.0x
P/E Ratio10.0x
P/S RatioIs ORCHPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORCHPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹9.05b |
| Cost of Revenue | ₹5.50b |
| Gross Profit | ₹3.55b |
| Other Expenses | ₹2.35b |
| Earnings | ₹1.20b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | 23.57 |
| Gross Margin | 39.19% |
| Net Profit Margin | 13.21% |
| Debt/Equity Ratio | 13.4% |
How did ORCHPHARMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Orchid Pharma Limited is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Angel Broking Private Limited |
| Sudarshan Padmanabhan | Batlivala & Karani Securities India Pvt. Ltd. |
| Pauline Lau | BofA Global Research |